Physician profile
Marcella Cudjoe
NPI 1689121857
$1,961.50
in general payments reported to CMS, 2019-2025
20 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.97 · 2022: $321 · 2023: $626 · 2024: $529 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,613.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $465.32 | 2022-2025 | |
| Novo Nordisk INC | $222.85 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $193.70 | 2022-2025 | |
| Lilly USA, LLC | $145.03 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $142.33 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $137.40 | 2023-2025 | Cologuard Collection Kit |
| Bausch Health US, LLC | $122.07 | 2023-2025 | Wellbutrin, Aplenzin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.84 | 2023-2025 | Xifaxan, Trulance |
| Almatica Pharma LLC | $77.40 | 2023-2024 | Loreev Xr, Gralise, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $60.89 | 2023 | Quviviq |
| Abbott Laboratories | $51.84 | 2022-2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $48.01 | 2022-2025 | Capvaxive |
| Kowa Pharmaceuticals America, INC. | $44.83 | 2024-2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $34.10 | 2025 | Trintellix |
| Paratek Pharmaceuticals, INC. | $27.97 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $17.71 | 2025 | Tirosint, Licart, Flector |
| Lundbeck LLC | $17.48 | 2025 | Rexulti |
| Daiichi Sankyo INC. | $16.80 | 2023 | Injectafer |
| Axsome Therapeutics, INC. | $16.54 | 2023 | Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.39 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcella Cudjoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.